CY1120323T1 - Φαρμακευτικες συνθεσεις για μειωση επιπλοκων απο οφθαλμικο στεροειδες - Google Patents

Φαρμακευτικες συνθεσεις για μειωση επιπλοκων απο οφθαλμικο στεροειδες

Info

Publication number
CY1120323T1
CY1120323T1 CY20181100606T CY181100606T CY1120323T1 CY 1120323 T1 CY1120323 T1 CY 1120323T1 CY 20181100606 T CY20181100606 T CY 20181100606T CY 181100606 T CY181100606 T CY 181100606T CY 1120323 T1 CY1120323 T1 CY 1120323T1
Authority
CY
Cyprus
Prior art keywords
steroids
pharmaceutical compositions
optical
ocular
reducing complications
Prior art date
Application number
CY20181100606T
Other languages
English (en)
Inventor
Keelung Hong
Luke S.S. Guo
Yun-Long Tseng
Sheue-Fang Shih
Po-Chun Chang
Chih-Chiang Tsai
Hong-hui LIN
Original Assignee
Taiwan Liposome Company, Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiwan Liposome Company, Ltd filed Critical Taiwan Liposome Company, Ltd
Publication of CY1120323T1 publication Critical patent/CY1120323T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε φαρμακευτικές συνθέσεις που περιλαμβάνουν συνδυασμό μείγματος κέικ λιπιδίου που περιλαμβάνει ένα ή περισσότερα φωσφολιπίδια, με ή χωρίς χοληστερόλη και διάλυμα στεροειδούς που περιλαμβάνει οφθαλμικό στεροειδές, παράγωγο αυτού, φαρμακευτικώς αποδεκτό άλας αυτού ή προφάρμακο αυτού, όπου η συνολική ποσότητα του φωσφολιπιδίου στην εν λόγω σύνθεση είναι περίπου 0,1 μmol έως λιγότερο από περίπου 2,5 μmol ανά 50 μικρολιτ. φαρμακευτικής σύνθεσης και οι παρενέργειες του οφθαλμικού στεροειδούς είναι μειωμένες. Η φαρμακευτική σύνθεση κατά προτίμηση χορηγείται μέσω της οφθαλμικής οδού για θεραπεία οφθαλμικών ασθενειών.
CY20181100606T 2012-02-10 2018-06-11 Φαρμακευτικες συνθεσεις για μειωση επιπλοκων απο οφθαλμικο στεροειδες CY1120323T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597189P 2012-02-10 2012-02-10
PCT/US2013/025390 WO2013119988A1 (en) 2012-02-10 2013-02-08 Pharmaceutical compositions to reduce complications of ocular steroid

Publications (1)

Publication Number Publication Date
CY1120323T1 true CY1120323T1 (el) 2019-07-10

Family

ID=48948063

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100606T CY1120323T1 (el) 2012-02-10 2018-06-11 Φαρμακευτικες συνθεσεις για μειωση επιπλοκων απο οφθαλμικο στεροειδες

Country Status (19)

Country Link
US (2) US10058616B2 (el)
EP (1) EP2797601B1 (el)
JP (1) JP6231995B2 (el)
KR (1) KR102060210B1 (el)
CN (2) CN107260679B (el)
AU (1) AU2013216861B2 (el)
BR (1) BR112014018393B1 (el)
CA (1) CA2862055C (el)
CY (1) CY1120323T1 (el)
DK (1) DK2797601T3 (el)
ES (1) ES2673330T3 (el)
HK (1) HK1201723A1 (el)
IN (1) IN2014MN01571A (el)
NZ (1) NZ628124A (el)
PT (1) PT2797601T (el)
RU (1) RU2660585C2 (el)
TR (1) TR201808592T4 (el)
TW (1) TWI620578B (el)
WO (1) WO2013119988A1 (el)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3445335A4 (en) * 2016-04-19 2020-03-04 Nanyang Technological University FORMULATIONS FORMING A SUB-CONJUNCTIVAL DEPOSIT FOR THE ADMINISTRATION OF MEDICATION AT THE EYE LEVEL
EP3691654A4 (en) 2017-09-25 2021-11-24 Surface Pharmaceuticals, Inc. OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES
CA3080166A1 (en) * 2017-11-21 2019-05-31 Axerovision, Inc. Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
BR112021000316A2 (pt) * 2018-07-09 2021-04-06 Taiwan Liposome Co. Ltd Métodos para reduzir complicações de esteroide intra-articular
SG11202106967QA (en) * 2018-12-27 2021-07-29 Surface Ophthalmics Inc Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
RU2716429C1 (ru) * 2019-05-29 2020-03-11 федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ лечения рецидивирующей эрозии роговицы различного генеза
CN111415822A (zh) * 2020-03-05 2020-07-14 沈阳农业大学 一种洋葱碳/二氧化锰阵列电极及其制备方法和应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
SE9100342D0 (sv) 1991-02-04 1991-02-04 Astra Ab Novel steroid esters
IL103907A0 (en) * 1992-11-27 1993-04-04 Pharmos Corp Ophthalmic compositions
EP1565165A2 (en) 2002-11-26 2005-08-24 Gilead Sciences, Inc. Liposomal formulations
KR101076053B1 (ko) 2003-02-04 2011-10-21 브라코 인터내셔날 비.브이. 초음파 조영제 및 그것의 제조방법
DK1768657T3 (da) * 2004-06-23 2008-12-01 Sirion Therapeutics Inc Fremgangsmåder og sammensætninger til at behandle ophthalmiske tilstande med retinylderivater
US7767217B2 (en) * 2006-03-14 2010-08-03 Foresight Biotherapeutics Ophthalmic compositions comprising povidone-iodine
US20070280902A1 (en) * 2006-06-01 2007-12-06 Laura Rabinovich-Guilatt Method for treating eye disease or conditions affecting the posterior segment of the eye
CA2655036A1 (en) * 2006-06-22 2007-12-27 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
US20080118500A1 (en) 2006-11-16 2008-05-22 Taiwan Liposome Company Sustained releasing composition via local injection for treating eye diseases
WO2009107753A1 (ja) 2008-02-29 2009-09-03 財団法人 名古屋産業科学研究所 後眼部到達用リポソーム及び後眼部疾患用医薬組成物
CN101502485A (zh) * 2009-03-20 2009-08-12 中国药科大学 地塞米松眼用纳米立方液晶制剂及其制备方法
CN101926769A (zh) * 2009-06-24 2010-12-29 天津金耀集团有限公司 地塞米松磷酸钠脂质体注射液
US8956600B2 (en) * 2009-08-10 2015-02-17 Taiwan Liposome Co. Ltd. Ophthalmic drug delivery system containing phospholipid and cholesterol
SG184127A1 (en) * 2010-03-19 2012-10-30 Massachusetts Inst Technology Lipid vesicle compositions and methods of use
US20130217657A1 (en) * 2011-12-21 2013-08-22 Insite Vision Incorporated Combination anti-inflammatory ophthalmic compositions

Also Published As

Publication number Publication date
EP2797601A4 (en) 2015-06-03
EP2797601A1 (en) 2014-11-05
BR112014018393B1 (pt) 2020-09-15
HK1201723A1 (en) 2015-09-11
ES2673330T3 (es) 2018-06-21
AU2013216861B2 (en) 2017-05-18
CA2862055C (en) 2020-03-10
CN107260679A (zh) 2017-10-20
RU2014132553A (ru) 2016-02-27
TWI620578B (zh) 2018-04-11
CN107260679B (zh) 2020-07-31
TW201338806A (zh) 2013-10-01
US10350294B2 (en) 2019-07-16
DK2797601T3 (en) 2018-06-14
JP6231995B2 (ja) 2017-11-15
US20150011520A1 (en) 2015-01-08
NZ628124A (en) 2016-06-24
US20180193461A1 (en) 2018-07-12
CA2862055A1 (en) 2013-08-15
AU2013216861A1 (en) 2014-08-07
CN104125830B (zh) 2018-01-16
KR20150008844A (ko) 2015-01-23
CN104125830A (zh) 2014-10-29
IN2014MN01571A (el) 2015-05-15
US10058616B2 (en) 2018-08-28
PT2797601T (pt) 2018-06-27
RU2660585C2 (ru) 2018-07-06
TR201808592T4 (tr) 2018-07-23
KR102060210B1 (ko) 2019-12-27
WO2013119988A1 (en) 2013-08-15
EP2797601B1 (en) 2018-03-21
BR112014018393A8 (pt) 2017-07-11
JP2015506983A (ja) 2015-03-05
BR112014018393A2 (el) 2017-06-20

Similar Documents

Publication Publication Date Title
CY1120323T1 (el) Φαρμακευτικες συνθεσεις για μειωση επιπλοκων απο οφθαλμικο στεροειδες
CY1123945T1 (el) Στοματικα σκευασματα αμεσης απελευθερωσης για υποκατεστημενες κιναζολινονες
CY1124446T1 (el) Μορφες δοσολογιας της ρουξολιτινιμπης παρατεταμενης αποδεσμευσης
AR086409A1 (es) Formulaciones de gel bioadhesivo de testosterona intranasal y uso del mismo para tratar hipogonadismo masculino
CY1123485T1 (el) Συνθεσεις και μεθοδοι για τη θεραπεια νοσων
ECSP18032223A (es) PIRAZOLO[3,4-b]PIRIDIN-6-CARBOXAMIDAS N-SULFONILADAS Y MÉTODO DE USO
CY1126136T1 (el) Μεθοδοι θεραπειας της αρθριτιδας
ECSP11011067A (es) Compuestos para el tratamiento de enfermedades y desórdenes oftalmológicos
CL2019002103A1 (es) Derivados de tirosinamida como inhibidores de rho-quinasa.
CR20180086A (es) Tricíclicos sustituidos y métodos para usarlos
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
CY1110199T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
CY1115991T1 (el) Φαρμακευτικη ψεκαζομενη συνθεση που περιλαμβανει ενα αναλογο της βιταμινης d προϊον και ενα κορτικοστεροειδες
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
MX2015012201A (es) Formulaciones modificadas de liposomas de docetaxel.
CY1122809T1 (el) Εστερικα προ-φαρμακα της [3-(1-(1η-ιμιδαζολ-4-υλ)αιθυλο)-2-μεθυλοφαινυλο) μεθανολης για τη θεραπεια οφθαλμικων νοσηματων
CR20110608A (es) Derivados de 1h-imidazo-[4,5-c]-quinolinona
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112015022476A2 (pt) composições de oxaliplatina de lipossoma para terapia de câncer
CY1108324T1 (el) Νεοι τεταρτοταγοποιημενοι εστερες κουινουκλιδινης
BR112014015333A8 (pt) composições lipossomais de clorito ou clorato
CR20140144A (es) Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
BR112015022415A2 (pt) composições de cisplatina lipossômica para terapia contra câncer